Day One

• Identifying the clinical and molecular criteria that differentiate a true ‘immune reset’ from traditional immune suppression techniques
• Understanding the current landscape of modalities achieving deep depletion of pathogenic immune memory cells necessary for immune rebooting
• Diving into the current hurdles to making immune resetting therapies a standard of care such as manufacturing scalability, off-target effects, safety and developing biomarkers

• Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
• Harnessing base editing to enable CAR T-cell combination therapies for B-cell targeting and beyond
• Discussing the possibility of B-cell reconstitution, focusing on whether the new B-cell compartment is “reset” to a non-autoreactive state

Join this session to hear the thoughts of experts who have successfully moved precision therapies from the oncology world into autoimmune diseases:

• Discussing whether the therapeutic goal should be complete depletion of peripheral B-cells or elimination of tissue resident B-cells that drive local pathology
• Addressing the risks associated at various level of depletion such as elevated BAFF
• Debating whether targeted depletion of specific pathogenic subsets is superior to non-selective deep depletion

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the immune resetting field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and technique applications.

• Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
• Harnessing available clinical data to inform target selection and match T-cell engager targets to the correct autoimmune indication
• Exploring the dosing challenges for high-efficacy T-cell engagers and determining whether intermittent high doses or continuous lower doses are optimal to balance efficacy and safety

• Understanding the mechanism of action for bi- and tri-specific antibodies enhancing cytotoxicity and phagocytosis through forced proximity for B-cell depletion
• Exploring how multi-specificity can overcome therapeutic resistance by targeting multiple antigens across the B-cell lineage
• Managing CRS risk for CD3 engagement in non-oncology populations in non-IgG-like multi-specific antibody constructs

• Novel T-cell engager for autoimmune diseases
• CD19 and BCMA targeting therapies for B-cell and plasma cell depletion
• New therapeutic approaches for drug for immune resetting

• Matching the modality to the pathogenic cell subset driving the disease
• Comparing the logistical and risk profiles of different classes of therapies and defining an acceptable risk-benefit ratio for large autoimmune patient populations
• Exploring the potential for combination therapies pairing a single dose reset agent with a subsequent maintenance modality to enhance durability and reduce relapse risk

Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own developments in the immune resetting world. Don’t miss out on the chance to submit your own posters and get ready to connect, learn, and present.

To submit your poster please contact info@hansonwade.com

• Understanding the therapeutic promise of CAR-T through its ability to cross the blood-brain barrier to achieve immune reset by eliminating the CNS-resident B-cells driving progressive MS pathology
• Leveraging the immune-resetting potential through early intervention to prevent the accumulation of permanent disability rather than treating symptoms of a late-stage progressive disease
• Establishing the clinical trial endpoints and regulatory frameworks necessary to prove the durable, long-term benefit and commercial viability of single-dose, curative therapies in a diverse patient population

• Securing Centre’s of Excellence with necessary oncology and rheumatology clinical expertise for patient screening lymphodepletion and toxicity management
• Addressing the competitive landscape around securing sites and managing site capacity that can risk delaying trial activation and delaying patient enrolment
• Improving patient enrolment practices through streamlining the patient journey, site education and increasing the centralization of trials to be more accessible

• Determining the optimal time to deploy B-cell depletion, focusing on using ‘immune reset’ therapies early in the course of the disease development
• Comparing the efficacy of standard peripheral B-cell depletion against next-generation therapies designed to achieve a complete, deep-depletion
• Defining new clinical endpoints and securing regulatory approval for a curative-intent treatment that aims to halt disease progression early across a broad, heterogeneous autoimmune patient population